{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:51:54Z","timestamp":1772347914624,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007113","name":"Arak University of Medical Sciences","doi-asserted-by":"publisher","award":["2954"],"award-info":[{"award-number":["2954"]}],"id":[{"id":"10.13039\/501100007113","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.intimp.2020.106895","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T10:40:55Z","timestamp":1598697655000},"page":"106895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: A randomized blinded trial"],"prefix":"10.1016","volume":"88","author":[{"given":"Morteza","family":"Mousavi-Hasanzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahador","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarvenaz","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aygin","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106895_b0005","first-page":"2386","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.intimp.2020.106895_b0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1651-2227.2005.tb01887.x","article-title":"Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease","volume":"94","author":"Zeller","year":"2005","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.intimp.2020.106895_b0015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.14414","article-title":"ITP: from idiopathic purpura to immune thrombocytopenia and back","volume":"175","author":"Stentoft","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.intimp.2020.106895_b0020","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106895_b0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2007.06635.x","article-title":"The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP","volume":"138","author":"Page","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106895_b0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/fcp.12198","article-title":"Comparison between IV immune globulin (IVIG) and anti-D globulin for treatment of immune thrombocytopenia: a randomized open-label study","volume":"30","author":"Eghbali","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106895_b0035","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOH.0b013e3282ba5552","article-title":"Pathogenesis of chronic immune thrombocytopenic purpura:","volume":"14","author":"Cines","year":"2007","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.intimp.2020.106895_b0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy","volume":"120","author":"Itp","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2020.106895_b0045","doi-asserted-by":"crossref","unstructured":"M. Battaglia, A. Stabilini, E. Tresoldi, Expanding human T regulatory cells with the mTOR-inhibitor rapamycin, in: MTOR, Springer, 2012, pp. 279\u2013293.","DOI":"10.1007\/978-1-61779-430-8_17"},{"key":"10.1016\/j.intimp.2020.106895_b0050","doi-asserted-by":"crossref","unstructured":"C. Miroux, O. Morales, A. Carpentier, S. Dharancy, F. Conti, E. Boleslowski, P. Podevin, C. Auriault, V. Pancr\u00e9, N. Delhem, Inhibitory effects of cyclosporine on human regulatory T cells in vitro, in: Transplant. Proc., Elsevier, 2009, pp. 3371\u20133374.","DOI":"10.1016\/j.transproceed.2009.08.043"},{"key":"10.1016\/j.intimp.2020.106895_b0055","doi-asserted-by":"crossref","unstructured":"M. Battaglia, A. Stabilini, M.-G. Roncarolo, Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells, Blood 105 (2005) 4743\u20134748.","DOI":"10.1182\/blood-2004-10-3932"},{"issue":"1","key":"10.1016\/j.intimp.2020.106895_b0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.2001.02893.x","article-title":"Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy","volume":"114","author":"Kappers-Klunne","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106895_b0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2141.2003.04254.x","article-title":"Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura","volume":"121","author":"Perrotta","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2020.106895_b0070","first-page":"2596","article-title":"Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group","volume":"121","author":"Rodeghiero","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.intimp.2020.106895_b0075","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/548085","article-title":"Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia","volume":"2013","author":"Li","year":"2013","journal-title":"Clin. Develop. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106895_b0080","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1002\/ajh.25119","article-title":"Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil","volume":"93","author":"Miano","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106895_b0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MPH.0000000000000818","article-title":"Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and evans syndrome (ES): a single institution\u2019s experience","volume":"39","author":"Jasinski","year":"2017","journal-title":"J. Pediatric Hematol.\/Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106895_b0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00002018-200528020-00006","article-title":"Benefit-risk assessment of sirolimus in renal transplantation","volume":"28","author":"Kuypers","year":"2005","journal-title":"Drug Safety"},{"issue":"6","key":"10.1016\/j.intimp.2020.106895_b0095","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence","volume":"37","author":"Issa","year":"2013","journal-title":"Am. J. Nephrol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106895_b0100","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920305907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920305907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:07:02Z","timestamp":1744492022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920305907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":20,"alternative-id":["S1567576920305907"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106895","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: A randomized blinded trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106895"}}